What is the share price of Innova Captab Ltd (INNOVACAP) today?
The share price of INNOVACAP as on 11th July 2025 is ₹875.40. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Innova Captab Ltd (INNOVACAP) share?
The past returns of Innova Captab Ltd (INNOVACAP) share are- Past 1 week: 0.90%
- Past 1 month: 0.83%
- Past 3 months: -0.03%
- Past 6 months: -13.81%
- Past 1 year: 74.07%
- Past 3 years: N/A%
- Past 5 years: 61.69%
What are the peers or stocks similar to Innova Captab Ltd (INNOVACAP)?
The peers or stocks similar to Innova Captab Ltd (INNOVACAP) include:What is the market cap of Innova Captab Ltd (INNOVACAP) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Innova Captab Ltd (INNOVACAP) is ₹5009.47 Cr as of 11th July 2025.What is the 52 week high and low of Innova Captab Ltd (INNOVACAP) share?
The 52-week high of Innova Captab Ltd (INNOVACAP) is ₹1260 and the 52-week low is ₹495.60.What is the PE and PB ratio of Innova Captab Ltd (INNOVACAP) stock?
The P/E (price-to-earnings) ratio of Innova Captab Ltd (INNOVACAP) is 39.06. The P/B (price-to-book) ratio is 5.22.Which sector does Innova Captab Ltd (INNOVACAP) belong to?
Innova Captab Ltd (INNOVACAP) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Innova Captab Ltd (INNOVACAP) shares?
You can directly buy Innova Captab Ltd (INNOVACAP) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Innova Captab Ltd
INNOVACAP Share Price
875.400.96% (+8.30)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
INNOVACAP Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
INNOVACAP Performance & Key Metrics
INNOVACAP Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 39.06 | 5.22 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.72 | 6.42 | 0.79% |
100%
Analysts have suggested that investors can buy this stock
from 2 analysts
Price Upside
Earnings Growth
Rev. Growth
INNOVACAP Company Profile
Innova Captab Ltd is an integrated pharmaceutical company involved in manufacturing and trading drugs, offering services across R&D, manufacturing, and distribution of generic formulations and branded generics.
SUNPHARMA
PE Ratio
36.71
36.71
1Y Return
5.71%
5.71%
Buy Reco %
87.10
87.10
CIPLA
PE Ratio
22.75
22.75
1Y Return
1.39%
1.39%
Buy Reco %
73.33
73.33
TORNTPHARM
PE Ratio
58.69
58.69
1Y Return
12.03%
12.03%
Buy Reco %
70.83
70.83
MANKIND
PE Ratio
53.44
53.44
1Y Return
21.78%
21.78%
Buy Reco %
81.25
81.25
DRREDDY
PE Ratio
18.46
18.46
1Y Return
4.87%
4.87%
Buy Reco %
50.00
50.00
INNOVACAP Sentiment Analysis
INNOVACAP Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
INNOVACAP Stock Summary · May 2025
In FY '25, the company achieved a robust revenue growth of 15%, driven by the successful launch of its Jammu facility and a strong performance in both domestic and international markets. Despite facing initial cannibalization effects from transitioning operations, management remains optimistic about future revenue, projecting a CAGR of 25% over the next three years. The CDMO segment showed resilience with a 6% to 8% volume growth, while the Domestic Branded Generics segment surged by 21%, reflecting strong market demand. Operational efficiency improvements and strategic investments in R&D are expected to enhance margins, even as the company navigates regional challenges and integrates its acquired brand. Overall, the sentiment around future growth remains positive, supported by effective cost management and a commitment to innovation.
INNOVACAP Stock Growth Drivers
INNOVACAP Stock Growth Drivers
6Strong Financial Performance
Innova Captab Limited reported robust financial results for FY '25, achieving total revenue of INR
Successful Launch of New Facility
The company successfully launched commercial production at its new facility in Kathua, Jammu, which has
INNOVACAP Stock Challenges
INNOVACAP Stock Challenges
0
Hmm, looks like there are nochallenges
INNOVACAP Forecast
INNOVACAP Forecasts
Price
Revenue
Earnings
INNOVACAP Share Price Forecast
INNOVACAP Share Price Forecast
2025
Current
₹875.40
Baseline
Forecast for Jul 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹875.40
Baseline
Forecast for Jul 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
INNOVACAP Company Revenue Forecast
INNOVACAP Company Revenue Forecast
2025
Current
₹1.26
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2025
Current
₹1.26
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
INNOVACAP Stock EPS (Earnings Per Share) Forecast
INNOVACAP Stock EPS (Earnings Per Share) Forecast
2025
Current
₹22.41
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹22.41
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
INNOVACAP
INNOVACAP
Income
Balance Sheet
Cash Flow
Annual Normal View
INNOVACAP Income Statement
INNOVACAP Income Statement
Annual Normal View
| Financial Year | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 356.03 | 374.62 | 412.03 | 803.41 | 935.58 | 1,093.80 | 1,255.73 | 1,255.72 | ||||||||
Raw Materials | 283.41 | 291.55 | 309.06 | 612.42 | 552.46 | 582.67 | 664.30 | 1,057.52 | ||||||||
| Power & Fuel Cost | 4.18 | 5.54 | 5.48 | 7.91 | 9.51 | 20.39 | 27.14 | |||||||||
| Employee Cost | 18.10 | 20.24 | 22.33 | 40.46 | 54.80 | 90.66 | 116.78 | |||||||||
| Selling & Administrative Expenses | 6.54 | 7.61 | 10.32 | 16.05 | 29.61 | 40.13 | 45.34 | |||||||||
| Operating & Other expenses | 2.79 | -2.55 | 8.99 | 27.67 | 166.36 | 193.01 | 203.96 | |||||||||
EBITDA | 41.01 | 52.23 | 55.85 | 98.90 | 122.84 | 166.94 | 198.21 | 198.20 | ||||||||
| Depreciation/Amortization | 10.67 | 10.08 | 5.59 | 7.50 | 11.08 | 15.96 | 24.78 | 24.77 | ||||||||
| PBIT | 30.34 | 42.15 | 50.26 | 91.40 | 111.76 | 150.98 | 173.43 | 173.43 | ||||||||
| Interest & Other Items | 5.58 | 4.63 | 3.93 | 5.68 | 19.97 | 21.46 | 2.41 | 2.41 | ||||||||
| PBT | 24.76 | 37.52 | 46.33 | 85.72 | 91.79 | 129.52 | 171.02 | 171.02 | ||||||||
| Taxes & Other Items | 4.89 | 9.65 | 11.85 | 21.77 | 23.84 | 35.18 | 42.76 | 42.78 | ||||||||
| Net Income | 19.87 | 27.87 | 34.48 | 63.95 | 67.95 | 94.34 | 128.26 | 128.24 | ||||||||
| EPS | 165.58 | 11.33 | 7.18 | 24.22 | 25.74 | 17.93 | 22.41 | 22.41 | ||||||||
| DPS | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
INNOVACAP Company Updates
INNOVACAP Stock Peers
INNOVACAP Past Performance & Peer Comparison
INNOVACAP Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Innova Captab Ltd | 39.06 | 5.22 | — |
| Sun Pharmaceutical Industries Ltd | 36.71 | 5.53 | 0.96% |
| Cipla Ltd | 22.75 | 3.83 | 1.08% |
| Torrent Pharmaceuticals Ltd | 58.69 | 14.78 | 0.18% |
INNOVACAP Stock Price Comparison
Compare INNOVACAP with any stock or ETFCompare INNOVACAP with any stock or ETF
INNOVACAP
INNOVACAP Holdings
INNOVACAP Shareholdings
INNOVACAP Promoter Holdings Trend
INNOVACAP Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
INNOVACAP Institutional Holdings Trend
INNOVACAP Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
INNOVACAP Shareholding Pattern
INNOVACAP Shareholding Pattern
INNOVACAP Shareholding History
INNOVACAP Shareholding History
Foreign Institutions
Mutual Funds Invested in INNOVACAP
Mutual Funds Invested in INNOVACAP
No mutual funds holding trends are available
Top 5 Mutual Funds holding Innova Captab Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 3.0667% | Percentage of the fund’s portfolio invested in the stock 0.81% | Change in the portfolio weight of the stock over the last 3 months -0.18% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 63/78 (-6) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 2.7941% | Percentage of the fund’s portfolio invested in the stock 1.07% | Change in the portfolio weight of the stock over the last 3 months -0.19% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 68/105 (-6) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.3412% | Percentage of the fund’s portfolio invested in the stock 1.01% | Change in the portfolio weight of the stock over the last 3 months -0.32% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 46/54 (-16) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing INNOVACAP stock
smallcases containing INNOVACAP stock
Looks like this stock is not in any smallcase yet.
INNOVACAP Events
INNOVACAP Events
INNOVACAP Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
INNOVACAP has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
INNOVACAP Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
INNOVACAP has not given any dividends in last 5 years
INNOVACAP Dividends
INNOVACAP Dividends
Hmm, looks like data is unavailable here. Please come back after some timeINNOVACAP Stock News & Opinions
INNOVACAP Stock News & Opinions
Articles & Videos
Corporate
Innova Captab to convene AGM
Innova Captab announced that the 21th Annual General Meeting(AGM) of the company will be held on 31 July 2025.Powered by Capital Market - Live
1 week agoCapital Market - Live
Earnings
Innova Captab consolidated net profit rises 2.96% in the March 2025 quarter
Net profit of Innova Captab rose 2.96% to Rs 29.57 crore in the quarter ended March 2025 as against Rs 28.72 crore during the previous quarter ended March 2024. Sales rose 19.84% to Rs 314.74 crore in the quarter ended March 2025 as against Rs 262.63 crore during the previous quarter ended March 2024. For the full year,net profit rose 35.94% to Rs 128.26 crore in the year ended March 2025 as against Rs 94.35 crore during the previous year ended March 2024. Sales rose 15.02% to Rs 1243.68 crore in the year ended March 2025 as against Rs 1081.31 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales314.74262.63 20 1243.681081.31 15 OPM %15.1514.50 -14.9714.28 - PBDT49.1142.95 14 195.80145.49 35 PBT39.3139.55 -1 171.02129.53 32 NP29.5728.72 3 128.2694.35 36 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Innova Captab announces board meeting date
Innova Captab will hold a meeting of the Board of Directors of the Company on 19 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Innova Captab consolidated net profit rises 36.09% in the December 2024 quarter
Net profit of Innova Captab rose 36.09% to Rs 34.20 crore in the quarter ended December 2024 as against Rs 25.13 crore during the previous quarter ended December 2023. Sales rose 4.62% to Rs 316.46 crore in the quarter ended December 2024 as against Rs 302.49 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales316.46302.49 5 OPM %14.7114.74 - PBDT50.7240.13 26 PBT45.5935.20 30 NP34.2025.13 36 Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Innova Captab standalone net profit rises 30.83% in the December 2024 quarter
Net profit of Innova Captab rose 30.83% to Rs 24.40 crore in the quarter ended December 2024 as against Rs 18.65 crore during the previous quarter ended December 2023. Sales rose 5.10% to Rs 248.53 crore in the quarter ended December 2024 as against Rs 236.46 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales248.53236.46 5 OPM %13.0712.91 - PBDT35.8528.48 26 PBT32.7725.51 28 NP24.4018.65 31 Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Innova Captab to table results
Innova Captab will hold a meeting of the Board of Directors of the Company on 5 February 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Spotlight
Innova Captab starts commercial production in Jammu facility
The said facility comprises four dedicated manufacturing blocks, including general, cephalosporin, penicillin, and penum, with a capability to manufacture a diverse range of products in oral solid dosages, dry powder injectables, dry syrup, BFS, large volume parenterals, and respiratory respule products. With this expansion, the company, at a consolidated level, has a total of five manufacturing facilities with nine independent manufacturing blocks. 'The facility has been established with a total capital outlay of more than Rs 450 crore, and with the start of commercial production, the company is poised to benefit from the Central Government's 'New Central Sector Scheme', for Capital Interest Subvention of 6% per annum and GST-linked incentive of 300% of investment made in plant and machinery in 10 years,' it added. Commenting on the recent development, Vinay Lohariwala, MD, Innova Captab, said, 'We are thrilled to announce the launch of commercial operations at our new Kathua, Jammu facility. This marks a significant milestone in our growth journey, enhancing both our production capacity and product basket. This will also enhance our ability to meet the evolving needs of our customers. This expansion is a strategic step in line with our long-term vision to strengthen our market position and fuel sustainable growth.' Innova Captab is an integrated pharmaceutical company in India with a presence across the pharmaceutical value chain, including research and development, manufacturing, drug distribution and marketing, and exports. The company has three businesses: CDMO (contract development and manufacturing organization) services and products, domestic branded generics, and international branded generics. The company's consolidated net profit increased 52.8% to Rs 35 crore on 12.5% rise in revenue from operations to Rs 318.20 crore in Q2 FY25 over Q2 FY24. Shares of Innova Captab tumbled 6.01% to currently trade at Rs 978 on the BSE. The counter has tanked 22.31% from its 52-week high of Rs 1,259 hit on 08 January 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Innova Captab commences commercial production at its facility in Jammu
Innova Captab has commenced commercial production at its state-of-the-art manufacturing facility in Kathua, Jammu. The facility comprises four dedicated manufacturing blocks including General, Cephalosporin, Penicillin and Penum with a capability to manufacture a diverse range of products in oral solid dosages, dry powder injectables, dry syrup, BFS, large volume parenterals and respiratory respule products. With this expansion, the company, at a consolidated level, have total five manufacturing facilities with nine independent manufacturing blocks. Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Innova Captab consolidated net profit rises 52.77% in the September 2024 quarter
Net profit of Innova Captab rose 52.77% to Rs 35.00 crore in the quarter ended September 2024 as against Rs 22.91 crore during the previous quarter ended September 2023. Sales rose 12.46% to Rs 318.20 crore in the quarter ended September 2024 as against Rs 282.94 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales318.20282.94 12 OPM %15.6314.31 - PBDT51.8035.01 48 PBT46.8130.18 55 NP35.0022.91 53 Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Innova Captab to announce Quarterly Result
Innova Captab will hold a meeting of the Board of Directors of the Company on 7 November 2024Powered by Capital Market - Live
8 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 27.37%, vs industry avg of 10%
Over the last 5 years, market share increased from 0.15% to 0.3%
Over the last 5 years, net income has grown at a yearly rate of 35.7%, vs industry avg of 19.96%